drugset / Trial / NCT06364072

Safety, Tolerability, Analgesic Effect, and Feasibility of Intranasal CT001 in Pediatric Patients

NCT06364072

Phase 2/3 Completed 155 enrolled Cessatech A/S
NaSingle-groupOpen-labelTreatment

Summary

The proposed study aims to investigate the safety, tolerability, analgesic efficacy, and feasibility of intranasal sufentanil/ketamine (CT001) in pediatric participants attending an acute care (i.e. emergency) setting. The study is a part of the clinical development plan for the development of CT001 nasal spray for treatment of acute pain in children.

Timeline

Start
2024-05-27
Primary completion
2025-05-09
Completion
2025-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule Intranasal
Subject Sufentanil Other / unclassified Intranasal

Indications

No indication recorded.